Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.
(2002) In BJU International 89(9). p.855-862- Abstract
- OBJECTIVE: To investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in men. PATIENTS AND METHODS: Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited. A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg). After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks. RESULTS: In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo). In the desmopressin group 28 (34%) patients... (More)
- OBJECTIVE: To investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in men. PATIENTS AND METHODS: Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited. A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg). After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks. RESULTS: In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo). In the desmopressin group 28 (34%) patients and in the placebo group two (3%) patients (P<0.001) had fewer than half the number of nocturnal voids relative to baseline; the mean number of nocturnal voids decreased from 3.0 to 1.7 and from 3.2 to 2.7, respectively, reflecting a mean decrease of 43% and 12% (P<0.001). The mean duration of the first sleep period increased by 59% (from 2.7 to 4.5 h) in the desmopressin group, compared with an increase of 21% (from 2.5 to 2.9 h) in the placebo group (P<0.001). The mean nocturnal diuresis decreased by 36% (from 1.5 to 0.9 mL/min) in the desmopressin group and by 6% (from 1.7 to 1.5 mL/min) in the placebo group (P<0.001). The mean ratio of night/24-h urine volume decreased by 23% and 1% (P<0.001), and the mean ratio of night/day urine volume decreased by 27% and increased by 3% (P<0.001) for the desmopressin and placebo groups, respectively. In the double-blind treatment period, similar numbers of patients had adverse events; 15 (17%) patients in the desmopressin and 16 (25%) patients in the placebo group. Most adverse events were mild. Serum sodium levels were <130 mmol/L in 10 (4%) patients and this occurred during dose-titration. CONCLUSIONS: Orally administered desmopressin is an effective and well-tolerated treatment for nocturia in men. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/108210
- author
- Mattiasson, Anders LU ; Abrams, P ; Van Kerrebroeck, P ; Walter, S and Weiss, J
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Renal Agents : administration & dosage, Middle Age, Male, Human, Double-Blind Method, Desmopressin : administration & dosage, Comparative Study, 80 and over, Aged, Adult, Administration, Oral, Treatment Outcome, Urination Disorders : drug therapy
- in
- BJU International
- volume
- 89
- issue
- 9
- pages
- 855 - 862
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000176083300006
- pmid:12010228
- scopus:0036098313
- ISSN
- 1464-4096
- DOI
- 10.1046/j.1464-410X.2002.02791.x
- language
- English
- LU publication?
- yes
- id
- 00279290-4cea-44f4-8b6c-6c104d15c94f (old id 108210)
- alternative location
- http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=12010228&dopt=Abstract
- date added to LUP
- 2016-04-01 12:11:55
- date last changed
- 2022-02-18 19:17:02
@article{00279290-4cea-44f4-8b6c-6c104d15c94f,
abstract = {{OBJECTIVE: To investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in men. PATIENTS AND METHODS: Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited. A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg). After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks. RESULTS: In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo). In the desmopressin group 28 (34%) patients and in the placebo group two (3%) patients (P<0.001) had fewer than half the number of nocturnal voids relative to baseline; the mean number of nocturnal voids decreased from 3.0 to 1.7 and from 3.2 to 2.7, respectively, reflecting a mean decrease of 43% and 12% (P<0.001). The mean duration of the first sleep period increased by 59% (from 2.7 to 4.5 h) in the desmopressin group, compared with an increase of 21% (from 2.5 to 2.9 h) in the placebo group (P<0.001). The mean nocturnal diuresis decreased by 36% (from 1.5 to 0.9 mL/min) in the desmopressin group and by 6% (from 1.7 to 1.5 mL/min) in the placebo group (P<0.001). The mean ratio of night/24-h urine volume decreased by 23% and 1% (P<0.001), and the mean ratio of night/day urine volume decreased by 27% and increased by 3% (P<0.001) for the desmopressin and placebo groups, respectively. In the double-blind treatment period, similar numbers of patients had adverse events; 15 (17%) patients in the desmopressin and 16 (25%) patients in the placebo group. Most adverse events were mild. Serum sodium levels were <130 mmol/L in 10 (4%) patients and this occurred during dose-titration. CONCLUSIONS: Orally administered desmopressin is an effective and well-tolerated treatment for nocturia in men.}},
author = {{Mattiasson, Anders and Abrams, P and Van Kerrebroeck, P and Walter, S and Weiss, J}},
issn = {{1464-4096}},
keywords = {{Renal Agents : administration & dosage; Middle Age; Male; Human; Double-Blind Method; Desmopressin : administration & dosage; Comparative Study; 80 and over; Aged; Adult; Administration; Oral; Treatment Outcome; Urination Disorders : drug therapy}},
language = {{eng}},
number = {{9}},
pages = {{855--862}},
publisher = {{Wiley-Blackwell}},
series = {{BJU International}},
title = {{Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.}},
url = {{https://lup.lub.lu.se/search/files/2823233/623610.pdf}},
doi = {{10.1046/j.1464-410X.2002.02791.x}},
volume = {{89}},
year = {{2002}},
}